8-K: Current report
Published on
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Richard Stark as a Director
Effective as of November 18, 2026, the Board of Directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), approved an increase the size of the Board from six directors to seven directors and appointed Richard Stark to fill the vacancy on the Board occasioned by such increase (the “Appointment”).
The following is certain biographical information regarding Mr. Stark:
Richard Stark, age 62, has more than 30 years of leadership experience in the medical technology industry. Since January 2024, he has served as Founder and Managing Member of MedTech Angels, an investment group focused on early-stage medical technology companies. Since January 2021, he has served as Chief Executive Officer of Innoblative Designs, Inc., a medical technology company developing advanced radiofrequency ablation technologies. Since January 2017, he has served as Founder and Principal of RAS Consulting Firm, LLC, advising healthcare companies, boards of directors and investors on commercialization strategy, business development, fundraising, strategic partnerships, mergers and acquisitions, and corporate growth initiatives. Previously, Mr. Stark served as Chief Executive Officer, President, and a member of the board of directors of Sanarus Technologies, a medical device company, from January 2018 to January 2021, where he led the company through the strategic transfer of its technology assets to Hologic, Inc. Prior to Sanarus, he served at AngioDynamics (Nasdaq: ANGO), a medical technology company, as Senior Vice President and General Manager, Global Oncology/Surgery, from January 2010 to January 2018 and as General Manager and Vice President, Sales & Marketing, Oncology/Surgery from January 2007 to January 2010. Earlier in his career, he held senior commercial leadership positions at RITA Medical Systems from January 1999 to January 2007 and leadership roles at Woodside Biomedical and Arrow International from January 1994 to January 1999. Mr. Stark currently serves on the boards of two medical device companies, Pleural Dynamics and Polyembo. Mr. Stark is qualified to serve as a director due to his extensive executive leadership experience, significant board and governance experience, deep knowledge of the medical technology sector, and demonstrated track record of driving growth, innovation, and strategic transactions across healthcare organizations.
The Board has determined that Mr. Stark qualifies as an independent director in accordance with the requirements of the Nasdaq Stock Market LLC. Mr. Stark has no family relationships with any of the Company’s directors or executive officers, and he is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Mr. Stark and any other persons pursuant to which he was selected as a director.
Prior to the Appointment, Mr. Stark had served as a consultant to the Company since December 5, 2024. In connection therewith, Mr. Stark provided strategic commercial advisory services to the Company as its Strategic Commercial Advisor pursuant to a Consulting Agreement, dated as of December 5, 2024, by and between the Company and Mr. Stark (as amended, the “Consulting Agreement”), as compensation for which Mr. Stark received solely options to purchase shares of the Company’s common stock (the “Common Stock”) granted under the Company’s Amended and Restated 2021 Omnibus Equity Incentive Plan (collectively, the “Consulting Options”) and no cash compensation. On November 11, 2026, the Company and Mr. Stark entered into a Consulting Termination Agreement pursuant to which the Consulting Agreement terminated effective as of November 15, 2026, and pursuant to which unvested Consulting Options to purchase 12,000 shares of Common Stock were forfeited by Mr. Stark.
Upon the Appointment, pursuant to Outside Director Compensation Policy of the Company (as amended, the “Policy”), on November 18, 2026, Mr. Stark was awarded 128,824 options to purchase shares of Common Stock having a grant date fair value of $120,000 in the aggregate (the “Initial Award”), with 1/36th of the Initial Award vesting each month on the same day of the month as the commencement of his service as an outside director, subject to his continued service through each vesting date. The Initial Award has a per share exercise price equal $1.12, the closing price of the Common Stock on the grant date, a term of ten years, and will vest in full upon a change in control of the Company, subject to his continued service through such date. In addition, pursuant to the Policy, Mr. Stark will (i) receive an annual cash retainer of $40,000, payable quarterly in arrears and prorated for any partial quarter of service, (ii) be eligible to receive the additional annual cash fees provided under the Policy for service as a chair or member of any committee of the Board to which he may be appointed, and (iii) on October 1, 2027, be automatically granted options to purchase shares of Common Stock having a grant date fair value of $70,000 in the aggregate, prorated based on the number of days elapsed from November 18, 2026 until October 1, 2027, with 1/12th of such award vesting monthly on the first day of each month thereafter, subject to his continued service. Thereafter, Mr. Stark will be eligible to receive the same compensation payable under the Policy to the Company’s other non-employee directors. Mr. Stark will also be reimbursed for his reasonable, customary and documented travel expenses to attend meetings of the Board and its committees.
On November 19, 2026, the Company issued a press release announcing the Appointment, a copy of which is filed as Exhibit 99.1 to this Form 8-K and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release, dated November 19, 2026, regarding the appointment of Richard Stark to the Board. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| RENOVORX, INC. | ||
| Date: November 20, 2026 | ||
| By: | /s/ Shaun R. Bagai | |
| Name: | Shaun R. Bagai | |
| Title: | Chief Executive Officer | |